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Promotion of culturally relevant
educational messages needed
Comprehensive educational messages are warranted so that
communities can adopt lifestyles that prevent the major disease
burdens, without having to focus on a specific condition. The
educational messages recommended for most NCDs are the
same: follow the correct diet, be physically active, decrease
stress levels, visit a doctor regularly, and screen for the
prevention and early detection of disease. However, we have to
modify these efforts taking cultural attitudes into account.
Weight loss should not be stressed specifically (especially in
sub-Saharan Africa); instead overall healthy behaviours should
be encouraged. Many NCDs are socially and culturally rooted;
until cultural norms related to overnutrition are better
understood, emphasis should be placed on eating more
nutritious food such as fresh fruits and vegetables, decreasing
salt and sugar intake, and increasing physical activity for
energy expenditure. In addition, existing beliefs about body
image need to be revised, using effective strategies. This will
only be possible with a heightened awareness and public
health mandate for curbing the growing epidemic of NCDs
and the risk factor of obesity that fuels it.
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The Medicines Control Council alerts all health care
professionals to new safety information regarding the
increased risk of hyperglycaemia and diabetes mellitus in
patients treated with the atypical antipsychotic medicines,
clozapine, olanzepine, quetiapine, risperidone and
ziprasidone.
Epidemiological studies have identified an increased risk of
treatment-emergent metabolic adverse events associated with
the atypical antipsychotic medicines. Lipid abnormalities and
weight gain are frequently occurring adverse effects
associated with the atypical antipsychotics. Abnormalities in
glucose metabolism range from hyperglycaemia in patients
with or without previously known diabetes mellitus to cases
of ketoacidosis, hyperosmolar coma and death. 
The background risk of type 2 diabetes mellitus in
schizophrenic patients as well as the increasing incidence of
diabetes mellitus in the general population may be
confounders. Patients with existing diabetes in whom
antipsychotic therapy is initiated should be closely monitored
for worsening of diabetic control.
All patients treated with atypical antipsychotic medicines
should be monitored for symptoms of hyperglycaemia.
Fasting blood glucose testing should be done on all patients
who develop symptoms of hyperglycaemia, or who are at risk
for type 2 diabetes. 
In some cases, hyperglycaemia resolved after
discontinuation of the atypical antipsychotic medicine;
however, there have been cases in which it has persisted
despite stopping therapy, requiring the prescription of anti-
diabetic medication.
Please continue reporting all adverse drug reactions
associated with atypical antipsychotic medicines and other
medicines to the National Adverse Drug Event Monitoring
Centre, tel. (021) 447-1618, fax (021) 448-6181.
Medicines Control Council
Cape Town
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